Calls for Broader Federal Cannabis Policy Reform
Members of the US Congress, including co-chairs of the Congressional Cannabis Caucus, recently convened with activists to advocate for broader federal cannabis policy reform. The discussions, reported by Marijuana Moment, emphasized the need to move beyond the incremental cannabis rescheduling process currently underway by the Trump administration.
Representative Ilhan Omar (D-MN), a co-chair of the Congressional Cannabis Caucus, highlighted public support for comprehensive cannabis legalization. She stated that millions of Americans believe cannabis should be legal and that the current approach has failed. Omar underscored the importance of avoiding criminal records for cannabis possession and redirecting resources towards education and economic opportunity rather than incarceration. She also stressed that legalization alone is insufficient without addressing justice and repair for communities impacted by the War on Drugs. This includes:
- Expunging records for nonviolent cannabis offenses.
- Reinvesting in communities disproportionately targeted by past policies.
- Ensuring equitable participation in the new cannabis economy for working-class individuals, small businesses, and entrepreneurs.
Representative Dina Titus (D-NV), another co-chair, noted that states have consistently led the federal government on cannabis policy. She argued that federal law needs to align with state-level developments, citing the moral, ethical, legal, and health-related reasons for such alignment. Titus also mentioned sponsoring legislation aimed at enabling federal drug officials to conduct more thorough research into cannabis effects.
Legislative Priorities and Regulatory Hurdles
The call for comprehensive federal cannabis policy reform extends to specific legislative actions. Representative Omar outlined immediate needs, including:
- Full descheduling of cannabis.
- Ending the federal hemp ban.
- Addressing barriers preventing legal cannabis businesses from accessing banking services.
- Protecting Americans in legal cannabis states, including veterans using medical marijuana and public housing residents, from federal punishment.
Representative Steve Cohen (D-TN) also participated in the event, asserting that the historical illegality of marijuana lacked a logical basis, attributing it to political motivations during the Nixon administration to target specific demographics. Cohen noted the Drug Enforcement Administration’s (DEA) resistance to rescheduling efforts during the Biden administration, describing the agency as a significant impediment to marijuana legislation.
As previously reported by Hemp Gazette, the federal government has initiated a process to move cannabis from Schedule I to Schedule III under the Controlled Substances Act for products regulated by a state medical cannabis license. This move, ordered by Acting Attorney General Todd Blanche, is reported to ease research barriers and provide tax benefits to state-licensed businesses. However, it does not broadly legalize cannabis, and products in state-legal recreational markets remain in Schedule I, pending further review.
Broader Congressional Actions and Industry Perspectives
Beyond the press conference, Congress continues to address various cannabis-related issues. The House is expected to consider an amendment allowing military veterans to receive medical marijuana recommendations from Department of Veterans Affairs (VA) doctors. Separately, the House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies approved a bill that would prevent federal officials from taking further steps to reschedule cannabis. The full House also passed a Farm Bill with provisions supporting industrial hemp producers, though it did not include language to delay or alter the federal recriminalization of hemp THC products scheduled for later this year.
The
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
